-+ 0.00%
-+ 0.00%
-+ 0.00%

PureTech Confirms Phase 3 SURPASS-IPF For Deupirfenidone (LYT-100) On Track For H1 2026 After FDA End-Of-Phase 2 Meeting

Benzinga·12/08/2025 07:30:37
Listen to the news
  • Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway
  • Phase 3 SURPASS-IPF trial remains on track to be initiated by PureTech's Founded Entity, Celea Therapeutics, in the first half of 2026